TQH2929 not checked

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.”In the company’s words, NCT06433531 on ClinicalTrials.gov
Tested for
Generalized Pustular Psoriasis
Main trialPhase 1
“This study is a multicenter, single-group, open-label study to evaluate the safety and tolerability of TQH2929 injection at a dose of 900mg in adult subjects with active Generalized Pustular Psoriasis (GPP), and to preliminarily evaluate the efficacy.”In the company’s words, NCT06433531 on ClinicalTrials.gov

Other drugs for Generalized Pustular Psoriasis

All 41 drugs for Generalized Pustular Psoriasis

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting 8 Jul 2025 A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)
Phase 2Terminated 30 Jul 2026 A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis
Phase 1Completed 2 Aug 2024 A Clinical Study of TQH2929 in Healthy Adult Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow TQH2929

Following is part of Solo: you see every change to TQH2929 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in